Most Frequent Side Effects Reported
Lurbinectedin (brand name Zepzelca), approved for metastatic small cell lung cancer, commonly causes hematologic toxicities like neutropenia (57% of patients), anemia (50%), and thrombocytopenia (36%). These often require dose adjustments or transfusions.[1][2]
Gastrointestinal Issues Patients Experience
Nausea affects 52% of patients, with vomiting in 30% and decreased appetite in 39%. Fatigue (50%) and constipation (22%) also occur frequently, sometimes leading to supportive care like antiemetics.[1][2]
Other Notable Effects in Trials
Common non-hematologic side effects include hyperglycemia (37%), peripheral edema (27%), increased creatinine (24%), and dyspnea (22%). Myelosuppression is the primary dose-limiting factor, with severe (grade 3/4) events in over 50% of cases across studies.[1][3]
How Side Effects Compare to Chemotherapy Standards
In the phase 2 IMforte trial for relapsed small cell lung cancer, lurbinectedin's myelosuppression profile mirrors topotecan but with lower rates of severe anemia (25% vs. 50%+). Real-world data shows similar patterns, though combination therapies amplify risks.[2][4]
What Happens with Long-Term Use or Overdose
Prolonged treatment increases cumulative myelotoxicity risks, with 10-15% of patients discontinuing due to adverse events. Overdose management focuses on supportive care, as no specific antidote exists; monitor for severe neutropenia lasting over 7 days.[1][3]
Patient Tips for Managing Effects
Guidelines recommend G-CSF prophylaxis for neutropenia, hydration for renal effects, and weekly blood monitoring during the first two cycles. Lung cancer patients with liver impairment face higher hepatotoxicity risks.[2][5]
[1]: Zepzelca (lurbinectedin) Prescribing Information, Jazz Pharmaceuticals, https://www.zepzelca.com/pdf/zepzelca-prescribing-information.pdf
[2]: Trigo J et al., Lung Cancer (2020), IMforte trial data, https://pubmed.ncbi.nlm.nih.gov/32403007/
[3]: FDA Approval Summary for Zepzelca, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213069s000lbl.pdf
[4]: Paz-Ares L et al., *J Clin Oncol* (2021), comparative efficacy/safety, https://ascopubs.org/doi/10.1200/JCO.20.0324
[5]: NCCN Guidelines for Small Cell Lung Cancer (v2.2023), https://www.nccn.org/guidelines